Literature DB >> 15930284

Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.

Don J Davidson1, Catherine Haskell, Sandy Majest, Abdullah Kherzai, David A Egan, Karl A Walter, Andrew Schneider, Earl F Gubbins, Larry Solomon, Zhebo Chen, Rick Lesniewski, Jack Henkin.   

Abstract

Kringle 5 (K5) of human plasminogen has been shown to inhibit angiogenesis by inducing the apoptosis of proliferating endothelial cells. Peptide regions around the lysine-binding pocket of K5 largely mediate these effects, particularly the peptide PRKLYDY, which we show to compete with K5 for the binding to endothelial cells. The cell surface binding site for K5 that mediates these effects has not been defined previously. Here, we report that glucose-regulated protein 78, exposed on cell surfaces of proliferating endothelial cells as well as on stressed tumor cells, plays a key role in the antiangiogenic and antitumor activity of K5. We also report that recombinant K5-induced apoptosis of stressed HT1080 fibrosarcoma cells involves enhanced activity of caspase-7, consistent with the disruption of glucose-regulated protein 78-procaspase-7 complexes. These results establish recombinant K5 as an inhibitor of a stress response pathway, which leads to both endothelial and tumor cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930284     DOI: 10.1158/0008-5472.CAN-04-3426

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  85 in total

Review 1.  Cancer-selective apoptotic effects of extracellular and intracellular Par-4.

Authors:  T Shrestha-Bhattarai; V M Rangnekar
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

Review 2.  Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.

Authors:  Peter C Gray; Wylie Vale
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

Review 3.  Targeting the embryonic gene Cripto-1 in cancer and beyond.

Authors:  Caterina Bianco; David S Salomon
Journal:  Expert Opin Ther Pat       Date:  2010-11-13       Impact factor: 6.674

Review 4.  Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential.

Authors:  Amy S Lee
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

5.  The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.

Authors:  Ravshan Burikhanov; Yanming Zhao; Anindya Goswami; Shirley Qiu; Steven R Schwarze; Vivek M Rangnekar
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

Review 6.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.

Authors:  Gidi Shani; Wolfgang H Fischer; Nicholas J Justice; Jonathan A Kelber; Wylie Vale; Peter C Gray
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

8.  GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78.

Authors:  Florence Delie; Patrick Petignat; Marie Cohen
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

9.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Authors:  Jami Mandelin; Marina Cardó-Vila; Wouter H P Driessen; Paul Mathew; Nora M Navone; Sue-Hwa Lin; Christopher J Logothetis; Anna Cecilia Rietz; Andrey S Dobroff; Bettina Proneth; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

10.  Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction.

Authors:  M Chen; Y Zhang; V C Yu; Y-S Chong; T Yoshioka; R Ge
Journal:  Cell Death Differ       Date:  2014-01-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.